Narlaprevir clinical trials
Also written SCH 900518.
How each study uses narlaprevir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Ritonavir (3) · Sofosbuvir (1) · Tenofovir (1) · Raltegravir (1) · Daclatasvir (1) · Boceprevir (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses narlaprevir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1CompletedPhase 2R-PharmNCT04246723Written as Narlaprevir
- A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched VolunteersCompletedPhase 1R-PharmNCT03832426Written as Narlaprevir
- A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsCompletedPhase 1R-PharmNCT03537404Written as Narlaprevir
- Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)CompletedPhase 3R-PharmNCT03833362Written as Narlaprevir
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1bCompletedPhase 2R-PharmNCT03485846Written as Narlaprevir
- Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)TerminatedPhase 2/3Merck Sharp & Dohme LLCNCT00689390Written as Narlaprevir
- A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00797745Written as SCH 900518
Codes
What other systems call narlaprevir · ClinicalTrials.gg INT005695
- MeSH (NLM) C552043narlaprevirOne source NLM
- UNII (FDA) 2857LA2O07NARLAPREVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27254268narlaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166554NarlaprevirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552043 | narlaprevir | One source NLM |
| UNII (FDA) | 2857LA2O07 | NARLAPREVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27254268 | narlaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166554 | Narlaprevir | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.